Amantadine in the treatment of Parkinson's disease and other movement disorders.
Rascol O, Fabbri M, Poewe W.
Lancet Neurol. 2021 Dec;20(12):1048-1056. doi: 10.1016/S1474-4422(21)00249-0. Epub 2021 Oct 19.
Neuroprotective effects of amantadine for experimental acute carbon monoxide poisoning.
Zengin EN, Kayır S, Doğan G, Zengin M, Akdağlı Ekici A, Yalvaç M, Ayaz E, Özcan O, Karaca O, Yağan Ö, Alagöz A.
Eur Rev Med Pharmacol Sci. 2022 Oct;26(19):6919-6927. doi: 10.26355/eurrev_202210_29872.
Memantine for dementia.
McShane R, Westby MJ, Roberts E, Minakaran N, Schneider L, Farrimond LE, Maayan N, Ware J, Debarros J.
Cochrane Database Syst Rev. 2019 Mar 20;3(3):CD003154. doi: 10.1002/14651858.CD003154.pub6.
The Use of Amantadine in Treating Extrapyramidal Symptoms in Organophosphates Poisoning in a Child.
Althaqafi W, Alanazi RI, Almeshari WK.
Case Rep Pediatr. 2023 Sep 4;2023:1632052. doi: 10.1155/2023/1632052. eCollection 2023.
Amantadine Improves Delayed Neuropsychiatric Sequelae of Carbon Monoxide Poisoning: A Case Report.
Nakano T, Hasegawa T, Suzuki D, Motomura E, Okada M.
Brain Sci. 2019 Oct 25;9(11):292. doi: 10.3390/brainsci9110292.
Extended-Release Amantadine for Levodopa-Induced Dyskinesia.
Dashtipour K, Tafreshi AR, Pahwa R, Lyons KE.
Expert Rev Neurother. 2019 Apr;19(4):293-299. doi: 10.1080/14737175.2019.1592677. Epub 2019 Mar 20.
Levodopa-Induced Dyskinesia in Parkinson's Disease: Pathogenesis and Emerging Treatment Strategies.
Kwon DK, Kwatra M, Wang J, Ko HS.
Cells. 2022 Nov 23;11(23):3736. doi: 10.3390/cells11233736.
Amantadine use in the French prospective NS-Park cohort.
Fabbri M, Rousseau V, Corvol JC, Sommet A, Tubach F, De Rycke Y, Bertille N, Selvarasa Y, Carvalho S, Chaigneau V, Brefel-Courbon C, Ory-Magne F, Tessier S, Tir M, Bereau M, Meissner WG, Thiriez C, Marques A, Remy P, Schneider V, Moro E, Defebvre L, Houeto JL, Prange S, Eusebio A, Geny C, Frismand S, Damier P, Reuther CG, Castelnovo G, Benatru I, De Maindreville AD, Drapier S, Maltête D, Lagha-Boukbiza O, Rascol O; French N. S.-Park network.
J Neural Transm (Vienna). 2024 Jul;131(7):799-811. doi: 10.1007/s00702-024-02772-4. Epub 2024 Apr 5.
GOCOVRI() (amantadine) extended-release capsules in Parkinson's disease.
Müller T.
Neurodegener Dis Manag. 2022 Feb;12(1):15-28. doi: 10.2217/nmt-2021-0028. Epub 2021 Dec 17.
Updating the recommendations for treatment of tardive syndromes: A systematic review of new evidence and practical treatment algorithm.
Bhidayasiri R, Jitkritsadakul O, Friedman JH, Fahn S.
J Neurol Sci. 2018 Jun 15;389:67-75. doi: 10.1016/j.jns.2018.02.010. Epub 2018 Feb 5.
